Fetuin: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
imported>Citation bot
m (Alter: journal. Add: pmc, pmid. Removed parameters. You can use this bot yourself. Report bugs here. | Headbomb)
Line 1: Line 1:
{{multiple issues|
{{Refimprove|date=July 2007}}
{{No footnotes|article|date=October 2009}}
}}
[[Image:FetuinAKnockout.jpg|thumb|250px|right|X-ray picture of a Fetuin-A knockout mouse (-/-) compared to a wildtype mouse (+/+). The bright dots in the fetuin-A deficient mouse indicate calcified lesions throughout the body.]]
[[Image:FetuinAKnockout.jpg|thumb|250px|right|X-ray picture of a Fetuin-A knockout mouse (-/-) compared to a wildtype mouse (+/+). The bright dots in the fetuin-A deficient mouse indicate calcified lesions throughout the body.]]
'''Fetuins''' are [[blood proteins]] that are made in the [[liver]] and secreted into the [[bloodstream]]. They belong to a large group of binding [[protein]]s mediating the transport and availability of a wide variety of cargo substances in the bloodstream. The best known representative of these carrier proteins is [[serum albumin]], the most abundant protein in the [[blood plasma]] of adult [[animal]]s. Fetuin is more abundant in fetal blood, hence the name "fetuin" (from Latin, ''fetus''). Fetal bovine serum contains more fetuin than albumin, while adult serum contains more albumin than fetuin.
'''Fetuins''' are [[blood proteins]] that are made in the [[liver]] and secreted into the [[bloodstream]]. They belong to a large group of binding [[protein]]s mediating the transport and availability of a wide variety of cargo substances in the bloodstream.<ref name="pmid22842477">{{cite journal | vauthors=Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, Ray S, Majumdar SS, Bhattacharya S | title=Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance | journal= [[Nature Medicine]] | volume=18 | issue=8 | pages=1279–1285 | year=2012 |url=http://basicmed.med.ncku.edu.tw/public/project/1216-1348566288-1.pdf | doi= 10.1038/nm.2851| pmid = 22842477 }}</ref> Fetuin-A is a major carrier protein of [[Fatty acid#Free fatty acids|free fatty acids]] in the circulation.<ref name="pmid22842477" /> The best known representative of carrier proteins is [[serum albumin]],{{Citation needed|date=September 2018}} the most abundant protein in the [[blood plasma]] of adult [[animal]]s. Fetuin is more abundant in fetal blood, hence the name "fetuin" (from Latin, ''fetus''). Fetal bovine serum contains more fetuin than albumin, while adult serum contains more albumin than fetuin.


== Family members ==
== Family members ==  


[[Human]] fetuin is synonymous with [[α2-HS-glycoprotein]] (genetic symbol AHSG), α2-HS, A2HS, AHS, HSGA, and fetuin-A. Fetuin-A exists as a single-copy gene in the human and mouse genomes. A closely related gene, [[fetuin-B]], also exists in the human, [[rat]], and [[mouse]] [[genome]]s. Like fetuin-A, fetuin-B is made predominantly by the liver and to a lesser extent by a number of secretory [[Biological tissue|tissues]]. Fetuins exist in all vertebrate genomes including [[fish]] and [[reptile]]s. Fetuins are members of a family of proteins that evolved from the protein [[cystatin]] by [[gene]] duplication and exchange of gene segments. Fetuins thus belong to the cystatin superfamily of proteins. Fetuin relatives within this superfamily are the [[histidine]]-rich glycoprotein (HRG) and kininogen (KNG).
[[Human]] fetuin is synonymous with [[α2-HS-glycoprotein]] (genetic symbol AHSG), α2-HS, A2HS, AHS, HSGA, and fetuin-A. Fetuin-A exists as a single-copy gene in the human and mouse genomes. A closely related gene, [[fetuin-B]], also exists in the human, [[rat]], and [[mouse]] [[genome]]s. Like fetuin-A, fetuin-B is made predominantly by the liver and to a lesser extent by a number of secretory [[Biological tissue|tissues]]. Fetuins exist in all vertebrate genomes including [[fish]] and [[reptile]]s. Fetuins are members of a family of proteins that evolved from the protein [[cystatin]] by [[gene]] duplication and exchange of gene segments. Fetuins thus belong to the cystatin superfamily of proteins. Fetuin relatives within this superfamily are the [[histidine]]-rich glycoprotein (HRG) and kininogen (KNG).
Line 53: Line 48:


== Animal studies ==
== Animal studies ==
The function of Fetuin-A in the body was determined by gene knockout technology in mice. Knocking out the gene for fetuin-A rendered the mice completely fetuin-A deficient. Feeding a [[mineral]]-rich [[diet (nutrition)|diet]] to fetuin-A-deficient mice resulted in widespread calcification (ectopic mineralization) of [[lung]], [[heart]], and [[kidney]]s in these mice. The calcification became drastically exacerbated when the fetuin-A knockout was combined with the genetic background DBA/2. The mouse strain DBA/2 is known for its proneness to calcify damaged tissues, a process called "dystrophic calcification". Fetuin-A deficiency dramatically increased the calcification proneness of these mice in that all mice sponteneously calcified throughout their body even without a mineral-rich diet or surgical tissue trauma. Fetuin-A is therefore regarded as a potent inhibitor of systemic calcification.


The function of Fetuin-A in the body was determined by gene knockout technology in mice. Knocking out the gene for fetuin-A rendered the mice completely fetuin-A deficient. Feeding a [[mineral]]-rich [[diet (nutrition)|diet]] to fetuin-A-deficient mice resulted in widespread calcification (ectopic mineralization) of [[lung]], [[heart]], and [[kidney]]s in these mice. The calcification became drastically exacerbated when the fetuin-A knockout was combined with the genetic background DBA/2. The mouse strain DBA/2 is known for its proneness to calcify damaged tissues, a process called "dystrophic calcification". Fetuin-A deficiency dramatically increased the calcification proneness of these mice in that all mice sponteneously calcified throughout their body even without a mineral-rich diet or surgical tissue trauma. Fetuin-A is therefore regarded as a potent inhibitor of systemic calcification.
[[Fatty acid#Free fatty acids|Free fatty acids]] cause Fetuin-A [[Gene expression|overexpression]] by increasing the pro-inflammatory protein [[NF-κB]].<ref name="pmid22842477" /> Fetuin-A has been shown to facilitate the binding of free fatty acids to [[TLR4]] receptors, thereby inducing [[insulin resistance]] in mice.<ref name="pmid22842477" />


== Human studies ==
== Human studies ==


Fetuin-A was originally discovered to be an inhibitor of vascular calcification in early 1990s. Since then the biologic roles attributed to fetuin-A have increased exponentially. Fetuin-A has been demonstrated to play an important role in free fatty acid induced insulin resistance in the liver. Increased fetuin-A in patients with pre-diabetes is associated with increased progression to diabetes and decreased reversal to normoglycemia. Hence fetuin-A is a predictor of adverse glycemic outcomes in pre-diabetes.<ref name="pmid24975463">{{cite journal | vauthors = Dutta D, Mondal SA, Kumar M, Hasanoor Reza AH, Biswas D, Singh P, Chakrabarti S, Mukhopadhyay S | title = Serum fetuin-A concentration predicts glycaemic outcomes in people with prediabetes: a prospective study from eastern India | journal = Diabet. Med. | volume = 31 | issue = 12 | pages = 1594–9 | year = 2014 | pmid = 24975463 | doi = 10.1111/dme.12539 }}</ref>{{Unreliable medical source|date=January 2015|sure=y}} Increased fetuin-A had been also been linked to increased occurrence of non-alcoholic fatty liver disease and cardiovascular events, believed to be due to its proinflammatory effects. Fetuin-A in contrast has also been demonstrated to have anti-inflammatory properties. It is a negative acute-phase reactant in sepsis and endotoxemia, promotes wound healing, and is neuroprotective in Alzheimer's disease. Decreased fetuin-A is a predictor of increased disease activity in obstructive lung disease, Crohn's disease, and [[ulcerative colitis]]. Differential effects on different toll like receptors in different tissues and organ systems may explain these pradoxical effects in different systems.<ref name="pmid25370330">{{cite journal | vauthors = Mukhopadhyay S, Mondal SA, Kumar M, Dutta D | title = Proinflammatory and antiinflammatory attributes of fetuin-a: a novel hepatokine modulating cardiovascular and glycemic outcomes in metabolic syndrome | journal = Endocr Pract | volume = 20 | issue = 12 | pages = 1345–51 | year = 2014 | pmid = 25370330 | doi = 10.4158/EP14421.RA }}</ref>{{Unreliable medical source|date=January 2015|sure=y}}
Fetuin-A was originally discovered to be an inhibitor of vascular calcification in early 1990s. Since then the biologic roles attributed to fetuin-A have increased exponentially. Fetuin-A has been demonstrated to play an important role in free fatty acid induced insulin resistance in the liver. Increased fetuin-A in patients with pre-diabetes is associated with increased progression to diabetes and decreased reversal to normoglycemia. Hence fetuin-A is a predictor of adverse glycemic outcomes in pre-diabetes.<ref name="pmid24975463">{{cite journal | vauthors = Dutta D, Mondal SA, Kumar M, Hasanoor Reza AH, Biswas D, Singh P, Chakrabarti S, Mukhopadhyay S | title = Serum fetuin-A concentration predicts glycaemic outcomes in people with prediabetes: a prospective study from eastern India | journal = Diabet. Med. | volume = 31 | issue = 12 | pages = 1594–9 | year = 2014 | pmid = 24975463 | doi = 10.1111/dme.12539 }}</ref>{{Unreliable medical source|date=January 2015|sure=y}} Obese persons have elevated circulating Fetuin-A, which can be reduced by [[metformin]], exercise, or weight loss. <ref name="pmid25468829">{{cite journal | vauthors=Trepanowski JF, Mey J, Varady KA | title=Fetuin-A: a novel link between obesity and related complications | journal= [[International Journal of Obesity]] | volume=39 |issue=5 | pages=734–741 | year=2015 |  doi=10.1038/ijo.2014.203 | pmid = 25468829 }}</ref>  Increased fetuin-A had been also been linked to increased occurrence of non-alcoholic fatty liver disease and cardiovascular events, believed to be due to its proinflammatory effects.<ref name="pmid29462898">{{cite journal | vauthors=Nascimbeni F, Romagnoli D, Ballestri S, Baldelli E, Lugari S, Sirotti V, Giampaoli V, Lonardo A | title=Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease? | journal= Diseases | volume=6 |issue=1 | pages=E17 | year=2018 | url=https://www.mdpi.com/2079-9721/6/1/17 | doi=10.3390/diseases6010017 | pmc=5871963 | pmid = 29462898 }}</ref>
 
Fetuin-A in contrast has also been demonstrated to have anti-inflammatory properties. It is a negative acute-phase reactant in sepsis and endotoxemia, promotes wound healing, and is neuroprotective in Alzheimer's disease. Decreased fetuin-A is a predictor of increased disease activity in [[obstructive lung disease]], [[Crohn's disease]], and [[ulcerative colitis]]. Differential effects on different toll like receptors in different tissues and organ systems may explain these pradoxical effects in different systems.<ref name="pmid25370330">{{cite journal | vauthors = Mukhopadhyay S, Mondal SA, Kumar M, Dutta D | title = Proinflammatory and antiinflammatory attributes of fetuin-a: a novel hepatokine modulating cardiovascular and glycemic outcomes in metabolic syndrome | journal = Endocr Pract | volume = 20 | issue = 12 | pages = 1345–51 | year = 2014 | pmid = 25370330 | doi = 10.4158/EP14421.RA }}</ref>{{Unreliable medical source|date=January 2015|sure=y}}


== References ==
== References ==

Revision as of 12:53, 27 November 2018

File:FetuinAKnockout.jpg
X-ray picture of a Fetuin-A knockout mouse (-/-) compared to a wildtype mouse (+/+). The bright dots in the fetuin-A deficient mouse indicate calcified lesions throughout the body.

Fetuins are blood proteins that are made in the liver and secreted into the bloodstream. They belong to a large group of binding proteins mediating the transport and availability of a wide variety of cargo substances in the bloodstream.[1] Fetuin-A is a major carrier protein of free fatty acids in the circulation.[1] The best known representative of carrier proteins is serum albumin,[citation needed] the most abundant protein in the blood plasma of adult animals. Fetuin is more abundant in fetal blood, hence the name "fetuin" (from Latin, fetus). Fetal bovine serum contains more fetuin than albumin, while adult serum contains more albumin than fetuin.

Family members

Human fetuin is synonymous with α2-HS-glycoprotein (genetic symbol AHSG), α2-HS, A2HS, AHS, HSGA, and fetuin-A. Fetuin-A exists as a single-copy gene in the human and mouse genomes. A closely related gene, fetuin-B, also exists in the human, rat, and mouse genomes. Like fetuin-A, fetuin-B is made predominantly by the liver and to a lesser extent by a number of secretory tissues. Fetuins exist in all vertebrate genomes including fish and reptiles. Fetuins are members of a family of proteins that evolved from the protein cystatin by gene duplication and exchange of gene segments. Fetuins thus belong to the cystatin superfamily of proteins. Fetuin relatives within this superfamily are the histidine-rich glycoprotein (HRG) and kininogen (KNG).

Α2-HS-glycoprotein
Identifiers
SymbolAHSG
Alt. symbolsFETUA, A2HS, HSGA
Entrez197
HUGO349
OMIM138680
RefSeqNM_001622
UniProtP02765
Other data
LocusChr. 3 q27.3
fetuin-B
Identifiers
SymbolFETUB
Alt. symbols16G2, Gugu
Entrez26998
HUGO3658
OMIM605954
RefSeqNM_014375
UniProtQ9UGM5
Other data
LocusChr. 3 q27.3

Animal studies

The function of Fetuin-A in the body was determined by gene knockout technology in mice. Knocking out the gene for fetuin-A rendered the mice completely fetuin-A deficient. Feeding a mineral-rich diet to fetuin-A-deficient mice resulted in widespread calcification (ectopic mineralization) of lung, heart, and kidneys in these mice. The calcification became drastically exacerbated when the fetuin-A knockout was combined with the genetic background DBA/2. The mouse strain DBA/2 is known for its proneness to calcify damaged tissues, a process called "dystrophic calcification". Fetuin-A deficiency dramatically increased the calcification proneness of these mice in that all mice sponteneously calcified throughout their body even without a mineral-rich diet or surgical tissue trauma. Fetuin-A is therefore regarded as a potent inhibitor of systemic calcification.

Free fatty acids cause Fetuin-A overexpression by increasing the pro-inflammatory protein NF-κB.[1] Fetuin-A has been shown to facilitate the binding of free fatty acids to TLR4 receptors, thereby inducing insulin resistance in mice.[1]

Human studies

Fetuin-A was originally discovered to be an inhibitor of vascular calcification in early 1990s. Since then the biologic roles attributed to fetuin-A have increased exponentially. Fetuin-A has been demonstrated to play an important role in free fatty acid induced insulin resistance in the liver. Increased fetuin-A in patients with pre-diabetes is associated with increased progression to diabetes and decreased reversal to normoglycemia. Hence fetuin-A is a predictor of adverse glycemic outcomes in pre-diabetes.[2][unreliable medical source] Obese persons have elevated circulating Fetuin-A, which can be reduced by metformin, exercise, or weight loss. [3] Increased fetuin-A had been also been linked to increased occurrence of non-alcoholic fatty liver disease and cardiovascular events, believed to be due to its proinflammatory effects.[4]

Fetuin-A in contrast has also been demonstrated to have anti-inflammatory properties. It is a negative acute-phase reactant in sepsis and endotoxemia, promotes wound healing, and is neuroprotective in Alzheimer's disease. Decreased fetuin-A is a predictor of increased disease activity in obstructive lung disease, Crohn's disease, and ulcerative colitis. Differential effects on different toll like receptors in different tissues and organ systems may explain these pradoxical effects in different systems.[5][unreliable medical source]

References

  1. ↑ 1.0 1.1 1.2 1.3 Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, Ray S, Majumdar SS, Bhattacharya S (2012). "Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance" (PDF). Nature Medicine. 18 (8): 1279–1285. doi:10.1038/nm.2851. PMID 22842477.
  2. ↑ Dutta D, Mondal SA, Kumar M, Hasanoor Reza AH, Biswas D, Singh P, Chakrabarti S, Mukhopadhyay S (2014). "Serum fetuin-A concentration predicts glycaemic outcomes in people with prediabetes: a prospective study from eastern India". Diabet. Med. 31 (12): 1594–9. doi:10.1111/dme.12539. PMID 24975463.
  3. ↑ Trepanowski JF, Mey J, Varady KA (2015). "Fetuin-A: a novel link between obesity and related complications". International Journal of Obesity. 39 (5): 734–741. doi:10.1038/ijo.2014.203. PMID 25468829.
  4. ↑ Nascimbeni F, Romagnoli D, Ballestri S, Baldelli E, Lugari S, Sirotti V, Giampaoli V, Lonardo A (2018). "Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease?". Diseases. 6 (1): E17. doi:10.3390/diseases6010017. PMC 5871963. PMID 29462898.
  5. ↑ Mukhopadhyay S, Mondal SA, Kumar M, Dutta D (2014). "Proinflammatory and antiinflammatory attributes of fetuin-a: a novel hepatokine modulating cardiovascular and glycemic outcomes in metabolic syndrome". Endocr Pract. 20 (12): 1345–51. doi:10.4158/EP14421.RA. PMID 25370330.

Further reading

Retrieved from "https://www.wikidoc.org/index.php?title=Fetuin&oldid=1532194"